RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice TargetHot
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $737 to $810.
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $737 to $810.